{
    "clinical_study": {
        "@rank": "161642", 
        "arm_group": {
            "arm_group_label": "Patients who are using Axitinib"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to monitor the usage of INLYTA\u00ae in real practice, including\n      the adverse events associated with INLYTA\u00ae."
        }, 
        "brief_title": "Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Investigators can choose any patient who is within the scope of I/E criteria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed as advanced RCC after failure of one prior systemic therapy.\n\n        Exclusion Criteria:\n\n          -  Any patient who does not agree that Pfizer or companies working on behalf of Pfizer\n             can use his/her information.\n\n          -  Patients with hypersensitivity to axitinib or to any other component of INLYTA\u00ae .\n\n          -  Patients under 18.\n\n          -  Pregnant women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Korea who has a disease for which Axitinib is indicated"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156895", 
            "org_study_id": "A4061075"
        }, 
        "intervention": {
            "arm_group_label": "Patients who are using Axitinib", 
            "description": "based on Axitinib approval", 
            "intervention_name": "Axitinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Korean PMS of Axitinib", 
            "Metastatic RCC ; 2nd line only"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061075&StudyName=Post%20Marketing%20Surveillance%20Study%20to%20Observe%20Safety%20and%20Efficacy%20of%20Inlyta%20in%20South%20Korea"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clinical nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and possible causality will be monitored in this study.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "bimonthly up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tumor response based on RECIST 1.1", 
                "measure": "Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "bimonthly up to 24 months"
            }, 
            {
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "bimonthly up to 24 months"
            }, 
            {
                "description": "Progression free survival (PFS) within limited follow up period", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "bimonthly up to 24 months"
            }, 
            {
                "measure": "Duration of Response (DR)", 
                "safety_issue": "No", 
                "time_frame": "bimonthly up to 24 months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}